2016-03-12T00:00:00.000-05:00
analysts,0.269067
protein signaling,-0.62688
loss,-0.705702
intentions,-0.296305
email newsletter,0.53367
rights,-0.29046
ties,-0.747705
study,-0.296305
immune-oncology treatments,-0.343903
cell squamous lung,-0.343903
decision,-0.52697
email address,0.269067
FP-1030,-0.448258
developing,-0.343903
180-day notice,-0.448258
Downgrades Daily,0.268671
enrollment,-0.296305
license,-0.448258
immune regulating treatments,-0.505313
new coverage,0.53367
drug,-0.710036
upgrades,0.289714
FP-1039,-0.343903
GlaxoSmithKline,-0.747705
agreement,-0.29046
refractory asthma,-0.266393
UK,-0.747705
prepared statement,0.259151
Prime Therapeutics,-0.747705
different therapies,-0.266393
GSK,-0.412112
concise daily summary,0.269067
program,-0.29046
pharmaceutical giant Bristol-Myers,-0.29046
cancer therapy development,-0.747705
ongoing mesothelioma trial,-0.747705
COPD,-0.266393
